Using our proprietary AI platform and metabolomic data from tissues and biofluids of patients, we discover treatments for metabolic diseases with unmet medical needs. With the growth of our database, we intelligently learn more about metabolic diseases and the manifestation of metabolic syndrome.
ReviveMed is an MIT spinout, artificial intelligence (AI)-driven drug discovery platform by uniquely leveraging data from small molecules or metabolites in the human body. Located in the heart of biotech innovation in Cambridge, ReviveMed uniquely overcomes the difficulties of identifying a large set of metabolites for each patient, based on technology that our team developed at MIT and published in Nature Methods. Our AI platform further combines the data from small molecules with other molecular data and translates these data into novel therapeutic insights for drug discovery. Currently, ReviveMed is collaborating with tier-one pharmaceutical companies and pursuing internal drug discovery, initially focused on metabolic diseases, including non-alcoholic fatty liver.
Total Funding: $1,500,000
Funding Stage: Seed
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2018
Deep Learning Data Scientist
Cambridge, Massachusetts
Computational Biologist
Cambridge, Massachusetts
